Results 41 to 50 of about 516,620 (290)

Targeting hepatocytes via the asialoglycoprotein-receptor [PDF]

open access: yes, 2010
The asialoglycoprotein-receptor (ASGP-R) is a C-type lectin predominantly expressed on the sinusoidal surface of mammalian hepatocytes and is responsible for the blood-clearance of desialylated glycoproteins by receptormediated endocytosis.
Stokmaier, Daniela
core   +1 more source

Membrane‐Bound Multimodal Plasmonic Transducers for Noninvasive, In Situ Monitoring and Control of CAR T Cells Against Heterogeneous Solid Tumors

open access: yesAdvanced Materials, EarlyView.
Membrane‐bound multimodal transducers enable longitudinal ultrasound‐guided photoacoustic monitoring and in situ thermal control of CAR T cells in heterogeneous solid tumors. Imaging correlates T cell trafficking with tumor response, distinguishing responders from nonresponders.
Myeongsoo Kim   +14 more
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

SOX5 Orchestrates Malignant Evolution via Promoter‐Centric Chromatin Remodeling in MYC‐Driven B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao   +6 more
wiley   +1 more source

A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control

open access: yesAdvanced Science, EarlyView.
Engineered STAb‐TON cells act as programmable living factories that continuously secrete inactive antibody modules, which assemble extracellularly into a functional T cell engager only upon small‐molecule administration. This externally controlled platform enables reversible, on‐demand regulation of antitumor immunity, establishing a new paradigm for ...
Susana Luengo‐Arias   +23 more
wiley   +1 more source

Site‐Specific Protein Bioconjugation Through Cellular Incorporation of Noncanonical Amino Acids

open access: yesAngewandte Chemie, EarlyView.
Genetic code expansion (GCE) enables site‐specific installation of noncanonical amino acids containing bioorthogonal conjugation handles, allowing precise, homogeneous protein modification. This review examines the principles of orthogonal translation, surveys the chemistries available for chemoselective labeling, and highlights emerging multi‐site ...
Rahul Sarkar   +2 more
wiley   +2 more sources

Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds

open access: yesAntibodies, 2018
Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not achievable with conventional monoclonal antibodies (mAbs).
Lilach Vaks   +9 more
doaj   +1 more source

Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies

open access: yesSTAR Protocols, 2022
Summary: Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources.
Danqing Li   +8 more
doaj   +1 more source

[Bispecific antibodies: what future?]

open access: yes, 2009
International audienceMonoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR ...
Bruno Robert   +3 more
core   +1 more source

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

open access: yesAdvanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy